A growing body of evidence from experimental studies that shows the essential role that magnesium exerts on glucose metabolism has been developed in last years, strongly suggesting that magnesium could plays an important roles in the reduction of the risk of developing type 2 diabetes.In the clinical setting, large epidemiological studies show that low dietary magnesium intake is associated with the increased risk of developing type 2 diabetes; however, results from randomized controlled clinical trials that have evaluated the beneficial effects of magnesium supplementation on glucose metabolism and insulin sensitivity are controversial.In this article we searched (in the electronic databases of Medline, Embase, and the Cochrane Controlled Trials Register up to June 2011) the evidence derived from epidemiological studies and clinical trials, about the relationship between magnesium and type 2 diabetes.The body of evidence from epidemiological studies consistently shows a strong inverse relationship between dietary magnesium intake and the risk of developing T2D; however, results from clinical trials are scarce and controversial.
Introduction
Although hypomagnesemia is a common feature in patients with type 2 diabetes (T2D), the hypomagnesemia also has been proposed as a risk factor of developing T2D.
Magnesium, the most abundant intracellular divalent cation [1, 2] , is involved as an essential cofactor in the enzymatic process of high-energy phosphate, energetic metabolism [3, 4] , and glucose metabolic pathways [4] [5] [6] [7] . Furthermore, clinical studies show that serum magnesium concentration is inversely associated with serum levels of C reactive protein (CRP) [8, 9] , suggesting that hypomagnesemia is related with the triggering of low-grade chronic inflammatory syndrome, which is associated with the decrease of insulin sensitivity [10] [11] [12] [13] [14] [15] [16] [17] . So, through impairment of enzymatic pathways involved in glucose transport and phosphorylation as well as by the triggering of low-grade chronic inflammation, magnesium deficiency is implicated in the decrease of insulin action [18] .
In addition, it has been reported that among individuals with serum magnesium deficiency, the decrease in insulin sensitivity is not appropriately compensated by the increase of beta-cell function [19, 20] and, that oral magnesium supplementation improves the ability of pancreatic ␤-cells to compensate the decreases in insulin sensitivity in non-diabetic subjects with significant hypomagnesemia [21] . These data strongly suggests that magnesium deficiency also is implicated in the decrease of insulin secretion.
Given that normal glucose tolerance is maintained by the balance between insulin secretion and insulin action, it is rationale to state that hypomagnesemia could play an important role in the development of glucose metabolic disorders and T2D.
In this article we searched (in the electronic databases of medline, embase, and the Cochrane Controlled Trials Register up to June 2011) the evidence derived from epidemiological studies and clinical trials, about the relationship between magnesium and type 2 diabetes.
The Based-population studies that tested the role of magnesium dietary intake were criteria for identifying the epidemiological studies; on the other hand, the randomized-controlled clinical trials using inorganic or organic magnesium salts, with duration of at least 12 weeks, were criteria for identifying the clinical trials.
Epidemiological studies
Magnesium is an important component of unprocessed foods such as whole grains, nuts, and green leafy vegetables; however the adoption of westernized diets has contributed to the reduction of magnesium intake in the vast majority of countries. On this regards, epidemiological studies have measured the association between magnesium intake and the risk of developing T2D.
Involving a total of 394,877 individuals enrolled in 9 follow-up studies (with 366,502 subjects and mean follow-up of 10.3 years), 7 cross-sectional studies (with 28,040 individuals), and 1 interventional life study (with 335 individuals), the role of magnesium intake in the customary diet, on glucose metabolism disorders and T2D has been tested in different age, sex, and ethnicity [9, 11, 16, 17, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] (table 1) .
Results of 15 (88.2%) of these studies consistently show that magnesium dietary intake play an independent role in ameliorating metabolic, inflammatory, and oxidative markers; benefits that have been documented in different age, sex, and ethnias [9, 11, 17, 22-31, 33, 34] .
A total of 9 (52.9%) studies show that magnesium intake is positively related with reduction of the risk for developing T2D; 3 (17.6%) with the beneficial effect on inflammation and oxidative markers; 2 (11.8%) with the reduction of prevalence of metabolic syndrome; and 1 (5.9%) with the improvement on insulin sensitivity. These results strongly supports the benefits of dietary magnesium intake on blood glucose metabolic disorders and T2D (table 1) .
On the other hand, 2 (11.8%) studies [16, 32] show that dietary magnesium intake is not appreciably associated neither reduction of the risk of T2D nor glucose levels and inflammation markers (table 1). These findings suggest that magnesium dietary intake by itself might be inadequate to modification the health status of subjects in high risk of developing T2D.
The discrepancy between studies could be related with additional nutrients involved in the diet, which vary according ethnicity and/or with the control of involved confounders. Furthermore, is necessary to take into account that usually epidemiological studies do not report magnesium status of participants at basal and final conditions; so, in these studies the magnesium status of participants is unknown. On this regard, is important to keep in mind that magnesium-induced changes on insulin sensitivity, insulin secretion, and glucose levels are inversely related with basal magnesium level; so, magnesium intake is likely more beneficial among individuals with magnesium deficiency.
However, on the basis that 88.2% of the analyzed studies show a beneficial effect of magnesium intake on glucose metabolism and reduction in the risk of developing T2D, it should be rationale that physicians and dietitians encourage to those individuals in high risk to the consumption of foods with elevated content of magnesium.
Clinical trials
Nonetheless the evidence from epidemiological studies showing the essential role of dietary magnesium intake on insulin-mediated glucose uptake, insulin sensitivity, and markers of chronic inflammation, randomized double blind controlled clinical trials regarding magnesium supplementation are scarce and have yielded inconsistent results.
A total of 12 randomized controlled studies that have enrolled 244 non-diabetic subjects and 345 type 2 diabetic patients have tested the efficacy of oral magnesium supplementation on insulin sensitivity and glucose levels [21, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . Five studies (41.7%) [21, [35] [36] [37] [38] , conducted in non-diabetic subjects, show a beneficial role of magnesium supplementation on insulin sensitivity; of these, one (8.3%) study shows also that magnesium supplementation improves beta-cell function to compensate for variations in insulin sensitivity in non-diabetic individuals with significant hypomagnesemia [21] . These finding suggests that magnesium supplementation plays an important role not only in the improvement of insulin sensitivity but also in the beta-cell function of non-diabetic subjects (table 2) .
Interestingly, in the study conducted by Paolisso et al. [38] it was reported that magnesium supplementation increases insulin secretion and action in elderly subjects. Because, in addition to inadequate nutrient intakes, decreased magnesium absorption, increased urinary magnesium loss, elevated frequency of chronic illnesses, and/or multiple drug use, magnesium deficiency is more common in older persons than generally suspected [46] . Thus, the finding by Paolisso et al. [38] , emphasizing the improves of glucose handling in the elderly, is of particular importance in the field. Unfortunately there are not more double blind studies that evaluate the effects of magnesium supplementation in geriatric populations.
Among non-diabetic subjects, magnesium aspartate (1 study), magnesium pidolate (1 study) magnesium citrate (1 study), and magnesium chloride (2 studies) were the magnesium supplements used.
On the other hand, results from 7 (58.3%) randomized double blind controlled clinical trials conducted in T2D subjects [39] [40] [41] [42] [43] [44] [45] are controversial with three (25.0%) studies showing that magnesium supplementation improves insulin sensitivity and glucose metabolic control [39] [40] [41] and, three (25.0%) studies showing no effect on glycemic control [43] [44] [45] . Results from the last one (8.3%) study conclude that only the prolonged use of magnesium with doses higher than usual is required to improve metabolic control [42] (table 2) .
The target population and magnesium salts used in these randomized controlled trials were: magnesium oxide (3 studies), magnesium chloride (2 studies), magnesium citrate (1 study), and magnesium pidolate (1 study). Unfavorable results in type 2 diabetic subjects were documented with the use of magnesium oxide, magnesium aspartate, and magnesium citrate (table 2) .
The controversial results in diabetic individuals who received magnesium supplementation could be related with several powerful confounders such as magnesium status of participants, additional magnesium intake in the customary diet, bioavailability of salt used, appropriate statistical power, duration of magnesium supplementation, duration of T2D, and the presence of chronic complications of diabetes, particularly complications affecting renal and intestinal function.
Interestingly, all studies that include nondiabetic individuals consistently show a beneficial effect of magnesium supplementation on glucose levels and insulin sensitivity, finding that could be related with the lower urinary loss of magnesium, that non-diabetic subjects exhibit as compared with type 2 diabetic subjects, who usually exhibited high urinary loss of magnesium, particularly the non-controlled diabetic subjects. This statement strongly suggests that patients with T2D might require higher dose of magnesium than the required by non-diabetic individuals.
Nonetheless that the benefits of chronic administration of magnesium in subjects with T2D is controversial and remains to be adequately evaluated, the routine measure of serum magnesium in diabetic patients and subjects in the high risk groups is recommendable as well as the advice for the intake of foods rich on magnesium, and/or magnesium supplements, particularly in those individuals who show low serum magnesium levels.
Further research based on randomized controlled clinical trials that includes long-term periods of magnesium supplementation and measurements of urinary magnesium levels is required.
Conclusions
The body of evidence from epidemiological studies consistently shows a strong inverse relationship between dietary magnesium intake and the risk of developing T2D.
Randomized controlled clinical trials that evaluate the benefits of magnesium supplementation on glucose levels in the individuals with T2D are scarce and controversial.
Among non-diabetic subjects, results of randomized controlled clinical trials are scarce but consistently show a beneficial effect of magnesium supplementation on insulin sensitivity and glucose levels.
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